During most of 2016, when shares of AbbVie (NYSE: ABBV) went up, so did shares of GlaxoSmithKline (NYSE: GSK). However, after the U.S. election surprise, the paths of these two drugmakers’ stocks have diverged. AbbVie is up, but Glaxo isn’t. That’s just a short-term snapshot, though. Which of these stocks is the better choice for investors over the long run? Here’s how AbbVie and GlaxoSmithKline stack up.
